Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

• Status: Completed
• Trial end date: 2008-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose: The primary objective of this study is to determine if chemotherapy with carboplatin and temozolomide significantly affects the response rates, or size of disease, in patients with brain metastases, originating from cancer in other parts of the body, compared to patients who have already been treated with radiation. Survival, causes of death, recurrence of disease in the central nervous system, toxicity, and quality of life will all be measured as secondary objective in this study.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Treatments: Carboplatin; Dacarbazine; Temozolomide

Criteria

Inclusion Criteria:

• Pathologically confirmed systemic cancer

Exclusion Criteria:

• Pregnant

• Known CNS meningeal involvement with cancer